Faisal Humayun

Faisal Humayun

Expertise: Oil and Gas, Electric Vehicles, Emerging Growth Stories

Education: Bachelor of Science, MBA with Specialization in Finance

About Faisal:
Faisal Humayun is an MBA in Finance and a senior research analyst with 14 years of experience in the field of equity, credit, industry and economic research. While working as a senior analyst, he has been involved in financial modelling, valuation analysis and credit rating.

As a freelancer, Faisal has authored over 1,500 articles for various publications that include Seeking Alpha, GuruFocus, Motley Fool, Trading Ideas and Red Pulse. His primary focus is on fundamental analysis using the top-down as well as bottom-up approach to stock selection.

Faisal is also an active trader with focus on price action trading strategy. A combination of long-term investing and short-term trading has produced decent results in a decade long exposure to equity markets. However, his favorite asset class is precious metals.

Additionally, Faisal has been researching cryptocurrencies in the last few quarters. His focus is not on the blue-chip coins, but on emerging altcoins that can be value creators.

You can learn more about Faisal at his profile on LinkedIn.

Recent Articles

3 High-Flying Stocks Set to Multiply Your Investment by 2025

These are stocks with 2x potential by 2025 and they represent fundamentally strong companies with high growth in an attractive industry.

Penny Stock Goldmines: 3 Gems to Grab for Massive Gains by 2024

These are the penny stocks to buy as they represent companies with impending business catalysts for positive price action.

3 Crypto Stocks to Buy for 100% Gains as Bitcoin Stabilizes

These are the crypto stocks to buy for multi-bagger returns by the end of 2024 with their attractive growth companies.

The 3 Most Undervalued Oil Stocks to Buy Now: August 2023

These are the oil stocks to buy and hold for total returns that consistently beat index returns.

The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023

These are the pharma stocks to buy at undervalued levels as they represent companies investing heavily in research and development.